Novartis Treatment May Help with VMA

Ocriplasmin

The investigational eye treatment ocriplasmin significantly resolved vitreomacular traction (VMT) and closed macular holes compared to placebo in patients with vitreomacular adhesion (VMA). That's the conclusion of two Phase III studies, involving 652 patients, that was published in the New England Journal of Medicine (NEJM), according to a press release from treatment's developer Novartis. VMA, including VMT and macular holes, is an age-related progressive eye disease that may lead to visual distortion, loss in visual acuity, and central blindness. More than 300,000 patients suffer from this disease in Europe alone.Read more.